Physician profile
Kenneth E Baird
NPI 1194755256
$8,374.43
in general payments reported to CMS, 2019-2025
38 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $385 · 2021: $914 · 2022: $5,803 · 2023: $466 · 2024: $393 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,098.47 | 2019-2022 | |
| Abbvie INC. | $828.57 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $395.56 | 2020-2025 | |
| Lilly USA, LLC | $232.10 | 2020-2023 | Jardiance, Zepbound |
| Abbott Laboratories | $186.05 | 2022-2025 | Freestyle Libre 3 |
| Eisai INC. | $143.09 | 2020-2022 | |
| Cerapedics INC. | $140.84 | 2022 | |
| Antares Pharma, INC. | $126.87 | 2020-2025 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $121.07 | 2022-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $117.77 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $96.90 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.23 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $68.73 | 2020-2022 | |
| Amarin Pharma, INC. | $57.95 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $56.12 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.